Stock Price Prediction

MDWD stock has a bullish outlook with a price target of $30, supported by the promising potential of EscharEx in chronic wound care, which is expected to capture significant market share. Despite a recent 11.86% decline in the stock price over six months, analysts maintain confidence in its growth due to its disruptive technology and strategic advancements. Current price levels around $16.72 may present an attractive entry point for long-term investors.

MDWD stock is currently trading at $19.59, down 1.51% recently. Bears argue that despite the promising potential of EscharEx, the stock's 11.86% decline over six months reflects weak market confidence, compounded by reduced revenue in Q3 due to lower BARDA funding. Additionally, HC Wainwright's lowered price target to $25 signals tempered expectations for near-term growth.

The market consensus for MDWD's revenue in the upcoming quarter is projected to be approximately $5.357M USD.

The market consensus for MDWD's eps in the upcoming quarter is projected to be approximately $0.56 USD.